Research ArticleOriginal Article

Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial

Cuicui Zhang, Tianqing Chu, Qiming Wang, Ying Cheng, Yongxiang Zhang, Ruili Wang, Leilei Ma, Chaonan Qian, Baohui Han and Kai Li
Cancer Biology & Medicine May 2024, 20230423; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0423

References

  1. 1.↵
    2. Rosenthal R,
    3. Cadieux EL,
    4. Salgado R,
    5. Bakir MA,
    6. Moore DA,
    7. Hiley CT, et al.
    Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019; 567: 479–85.
    OpenUrlPubMed
  2. 2.↵
    2. Topalian SL,
    3. Hodi FS,
    4. Brahmer JR,
    5. Gettinger SN,
    6. Smith DC,
    7. McDermott DF, et al.
    Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab. JAMA Oncol. 2019; 5: 1411–20.
    OpenUrl
  3. 3.↵
    2. Li JK,
    3. Xu JY,
    4. Yang MY,
    5. Zhou Q.
    Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era. Cancer Biol Med. 2022; 19: 569–72.
    OpenUrlFREE Full Text
  4. 4.↵
    2. Zhu PF,
    3. Lu HR,
    4. Wang MX,
    5. Chen K,
    6. Chen ZL,
    7. Yang L.
    Targeted mechanical forces enhance the effects of tumor immunotherapy by regulating immune cells in the tumor microenvironment. Cancer Biol Med. 2023; 20: 44–55.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    2. Sharma P,
    3. Hu-Lieskovan S,
    4. Wargo JA,
    5. Ribas A.
    Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017; 168: 707–23.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Manegold C,
    3. Dingemans AC,
    4. Gray JE,
    5. Nakagawa K,
    6. Nicolson M,
    7. Peters S, et al.
    The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol. 2016; 12: 194–207.
    OpenUrl
  7. 7.↵
    2. Zhou CC,
    3. Gao GH,
    4. Wang YN,
    5. Zhao J,
    6. Chen GY,
    7. Liu ZH, et al.
    Efficacy of PD-1 monoclonal antibody SHR-1210 plus apatinib in patients with advanced nonsquamous NSCLC with wild-type EGFR and ALK. J Clin Oncol. 2019; 37(suppl 15): 9112.
    OpenUrl
  8. 8.↵
    2. Qiu LP,
    3. Zhao X,
    4. Shi WW,
    5. Sun SJ,
    6. Zhang GQ,
    7. Sun Q, et al.
    Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients. Medicine. 2020; 99: e20545.
  9. 9.↵
    2. Socinski MA,
    3. Nishio M,
    4. Jotte RM,
    5. Cappuzzo F,
    6. Orlandi F,
    7. Stroyakovskiy D, et al.
    IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021; 16: 1909–24.
    OpenUrlCrossRefPubMed
  10. 10.↵
    2. Zhang XL,
    3. Zhang Y,
    4. Jia YN,
    5. Qin TT,
    6. Zhang CC,
    7. Li YY, et al.
    Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling. Cancer Biol Med. 2020; 17: 418–32.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    2. Liu SC,
    3. Qin TT,
    4. Liu ZJ,
    5. Wang J,
    6. Jia YN,
    7. Feng YF, et al.
    Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 2020; 11: 309.
    OpenUrl
  12. 12.↵
    2. Bordry N,
    3. Broggi MAS,
    4. de Jonge KD,
    5. Schaeuble K,
    6. Gannon PO,
    7. Foukas PG, et al.
    Lymphatic vessel density is associated with CD8+ T cell infiltration and immunosuppressive factors in human melanoma. Oncoimmunology. 2018; 7: e1462878.
  13. 13.↵
    2. Han BH,
    3. Li K,
    4. Wang QM,
    5. Zhang L,
    6. Shi JH,
    7. Wang ZH, et al.
    Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018; 4: 1569–75.
    OpenUrl
  14. 14.
    2. Cheng Y,
    3. Wang QM,
    4. Li K,
    5. Shi JH,
    6. Liu Y,
    7. Wu L, et al.
    Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled phase 2 study. Br J Cancer. 2021; 125: 366–71.
    OpenUrl
  15. 15.↵
    2. Li DP,
    3. Chi Y,
    4. Chen XH,
    5. Ge MH,
    6. Zhang Y,
    7. Guo ZM, et al.
    Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB trial. Clin Cancer Res. 2021; 27: 3567–75.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    2. Chu TQ,
    3. Zhong RB,
    4. Zhong H,
    5. Zhang B,
    6. Zhang W,
    7. Shi CL, et al.
    Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. J Thorac Oncol. 2021; 16(4): 643–52.
    OpenUrlPubMed
  17. 17.↵
    2. Han B,
    3. Li K,
    4. Wang Q,
    5. Cheng Y,
    6. Yang L,
    7. Li YC.
    The efficacy and safety of TQ-B2450 alone/with anlotinib in previously treated advanced nonsmall cell lung cancer (NSCLC): a multicenter, randomized, double-blind clinical trial: LBA4. EMSO; 2021.
  18. 18.↵
    2. Eisenhauer EA,
    3. Therasse P,
    4. Bogaerts J,
    5. Schwartz LH,
    6. Sargent D,
    7. Ford R, et al.
    New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228–47.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    2. Nishino M,
    3. Giobbie-Hurder A,
    4. Gargano M,
    5. Suda M,
    6. Ramaiya NH,
    7. Hodi FS.
    Developing a common language for tumor response to immunotherapy: Immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013; 19: 3936–43.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    2. Wimberly H,
    3. Brown JR,
    4. Schalper K,
    5. Haack H,
    6. Silver MR,
    7. Nixon C, et al.
    PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res. 2015; 3: 326–32.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    2. De Marchi P,
    3. Leal LF,
    4. Duval da Silva V,
    5. da Silva ECA,
    6. Cordeiro de Lima VC,
    7. Reis RM.
    PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in Non-Small Cell Lung Cancer (NSCLC). J Clin Pathol. 2021; 74: 735–40.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    2. Qiu L,
    3. Jin X,
    4. Wang JJ,
    5. Tang XD,
    6. Fang X,
    7. Li SJ, et al.
    Plasma neutrophil-to-lymphocyte ratio on the third day postburn is associated with 90-day mortality among patients with burns over 30% of total body surface area in two Chinese burns centers. J Inflam Res. 2021; 14: 519–26.
    OpenUrl
  23. 23.↵
    2. Zhang W,
    3. Wang J,
    4. Wang QM,
    5. Cheng Y,
    6. Yang L,
    7. Li YC, et al.
    A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer. Lung Cancer. 2023; 184: 107353.
  24. 24.↵
    2. Ghahremanloo A,
    3. Soltani A,
    4. Modaresi SMS,
    5. Hashemy SI.
    Recent advances in the clinical development of immune checkpointblockade therapy. Cell Oncol (Dordr). 2019; 42: 609–26.
    OpenUrl
  25. 25.↵
    2. Huang Y,
    3. Kim BYS,
    4. Chan CK,
    5. Hahn SM,
    6. Weissman IL,
    7. Jiang W.
    Improving immune–vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018; 18: 195–203.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Tian L,
    3. Goldstein A,
    4. Wang H,
    5. Ching Lo H,
    6. Sun Kim I,
    7. Welte T, et al.
    Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017; 544: 250–4.
    OpenUrlCrossRefPubMed
  27. 27.↵
    2. Choueiri TK,
    3. Motzer RJ,
    4. Rini BI,
    5. Haanen J,
    6. Campbell MT,
    7. Venugopal B, et al.
    Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020; 31: 1030–9.
    OpenUrlCrossRefPubMed
  28. 28.↵
    2. Choi HW,
    3. Naskar M,
    4. Seo HK,
    5. Lee HW.
    Tumor-associated mast cells in urothelial bladder cancer: optimizing immuno-oncology. Biomedicines. 2021; 9: 1500.
    OpenUrl
  29. 29.↵
    2. Liu SC,
    3. Qin TT,
    4. Jia YN,
    5. Li K.
    PD-L1 expression is associated with VEGFA and LADC patients’ survival. Front Oncol. 2019; 9: 189.
    OpenUrl
  30. 30.↵
    2. Su YD,
    3. Luo BY,
    4. Lu Y,
    5. Wang DW,
    6. Yan J,
    7. Zheng J, et al.
    Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma. Clin Cancer Res. 2022; 28: 793–809.
    OpenUrl
  31. 31.↵
    2. Jiang XD,
    3. Dai P,
    4. Qiao Y,
    5. Wu J,
    6. Song DA,
    7. Li SQ.
    Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer. Clin Transl Oncol. 2012; 14: 437–43.
    OpenUrlPubMed
  32. 32.↵
    2. Lane SR,
    3. Femel J,
    4. Breazeale AP,
    5. Loo CP,
    6. Thibault G,
    7. Kaempf A, et al.
    IFN-γ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med. 2018; 215: 3057–74.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    2. Qin TT,
    3. Liu ZJ,
    4. Wang J,
    5. Xia JL,
    6. Liu SC,
    7. Jia YN, et al.
    Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling. Cancer Biol Med. 2020; 17: 753–67.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    2. Herzog BH,
    3. Fu J,
    4. Wilson SJ,
    5. Hess PR,
    6. Sen A,
    7. McDaniel JM, et al.
    Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature. 2013; 502: 105–9.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    2. Subramanian H,
    3. Grailer JJ,
    4. Ohlrich KC,
    5. Rymaszewski AL,
    6. Loppnow JJ,
    7. Kodera M, et al.
    Signaling through L-selectin mediates enhanced chemotaxis of lymphocyte subsets to Secondary lymphoid tissue chemokine. J Immunol. 2012; 188: 3223–36.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    2. Asrir A,
    3. Tardiveau C,
    4. Coudert J,
    5. Laffont R,
    6. Blanchard L,
    7. Bellard E, et al.
    Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell. 2022; 14; 318–34.e9.
    OpenUrl
  37. 37.↵
    2. Xiong Q,
    3. Qin B,
    4. Xin L,
    5. Yang B,
    6. Song Q,
    7. Wang Y, et al.
    Real-world efficacy and safety of anlotinib with and without immunotherapy in advanced non-small cell lung cancer. Front Oncol. 2021; 11: 659380.
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords